Deal Intelligence Blog

Insights for Deal Professionals

Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.

356 articles

All Buyer Intelligence Deal Analysis Market Trend Deal Trends How Much Comparison Industry Analysis Market Analysis Negotiation Strategy Deal Strategy

FeaturedDeal Strategy

Understanding the Phase Transition Premium in Biotech Licensing

Phase 2 biotech assets consistently command 2-4x the deal values of Phase 1 programs. We explain the mechanics behind the phase transition premium and how to use it in negotiations.

March 17, 20267 min read

Read article

Benchmark Your Next Deal

Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.

Try Solidus